The reiteration of a Buy rating suggests continued confidence in Apellis Pharmaceuticals' prospects. However, the reduction in the price target may reflect a reassessment of potential risks or a more conservative outlook on the company's future performance. This mixed signal could lead to a neutral short-term impact on the stock price as the market digests both the positive endorsement and the lowered expectations.